Functional assays of drug-target engagement on circulating tumor cells captured from patient blood correlate with patient progression

Brian J. Kirby, Erica D. Pratt, Steven M. Santana, James P. Smith, Jason P. Gleghorn, Mona Jodari, Ganjun Gakhar, Matt Loftus, He Liu, Neil H. Bander, David M. Nanus, Paraskevi A. Giannakakou

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Chemotherapeutic treatment is limited by the heterogeneous and short-lived efficacy of therapy. Functional assays of tu-bulin bundling on microchip-captured circulating tumor cells (CTCs) in late-stage castrate-resistance prostate cancer are presented for the first time, and results are interpreted in the context of patient progression. Anti-PSMA capture leads to high capture rates of cells that remain functionally responsive to chemotherapies. These results point to the potential for microflu- idicallycaptured CTCs to inform clinical care in this patient population.

Original languageEnglish (US)
Title of host publication15th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2011, MicroTAS 2011
Pages2068-2070
Number of pages3
StatePublished - 2011
Event15th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2011, MicroTAS 2011 - Seattle, WA, United States
Duration: Oct 2 2011Oct 6 2011

Publication series

Name15th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2011, MicroTAS 2011
Volume3

Other

Other15th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2011, MicroTAS 2011
Country/TerritoryUnited States
CitySeattle, WA
Period10/2/1110/6/11

Keywords

  • Antibody
  • CTC
  • Cancer
  • Chemotherapy
  • Circulating tumor cell
  • Clinical diagnostics
  • J591
  • Microfluidics
  • PSMA

ASJC Scopus subject areas

  • Control and Systems Engineering

Fingerprint

Dive into the research topics of 'Functional assays of drug-target engagement on circulating tumor cells captured from patient blood correlate with patient progression'. Together they form a unique fingerprint.

Cite this